Hepatican Ltd Invited to Speak at AMC 2025: Shaping the Future of Advanced Therapy Manufacturing

UCL Professor Clare Selden, Founder of Hepatican Ltd, has been invited to speak at the upcoming ATMP Manufacturing Community (AMC) event, set to take place on Thursday, May 1st, 2025, in Newcastle. The event, themed "Scaling Manufacture to Meet Upcoming Commercial Demand," will bring together experts from across the sector to tackle one of the most pressing challenges in the field: how to transition advanced therapy medicinal products (ATMPs) from lab-scale innovation to large-scale commercial production. The talk titled “Hepatican – A novel treatment to rescue patients with liver failure” will be presented in Session 2 -  Innovative Technologies.

The conference will be held at The Catalyst, located in Newcastle’s cutting-edge Helix innovation district. Organized by the AMC event team, the day will feature talks, panel discussions, and networking sessions aimed at sharing practical insights, regulatory considerations, and technological solutions to support the industrial-scale manufacture of ATMPs.

The invitation to speak at this prestigious event reflects the growing recognition of academic and clinical leaders in driving forward the commercial readiness of cell and gene therapies. As the industry moves closer to delivering transformative treatments to broader patient populations, forums like AMC 2025 are crucial for aligning expertise across research, regulation, and manufacturing.